These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37143606)

  • 1. Facing Antitubercular Resistance: Identification of Potential Direct Inhibitors Targeting InhA Enzyme and Generation of 3D-pharmacophore Model by in silico Approach.
    El Haddoumi G; Mansouri M; Bendani H; Bouricha EM; Kandoussi I; Belyamani L; Ibrahimi A
    Adv Appl Bioinform Chem; 2023; 16():49-59. PubMed ID: 37143606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
    Rawat R; Whitty A; Tonge PJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
    Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
    J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant.
    Zhao X; Yu H; Yu S; Wang F; Sacchettini JC; Magliozzo RS
    Biochemistry; 2006 Apr; 45(13):4131-40. PubMed ID: 16566587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational approach identifies protein off-targets for Isoniazid-NAD adduct: hypothesizing a possible drug resistance mechanism in
    Hassan S; Sudhakar V; Nancy Mary MB; Babu R; Doble M; Dadar M; Hanna LE
    J Biomol Struct Dyn; 2020 Apr; 38(6):1697-1710. PubMed ID: 31094664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
    da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
    J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational approach to understanding the mechanism of action of isoniazid, an anti-TB drug.
    Jena L; Waghmare P; Kashikar S; Kumar S; Harinath BC
    Int J Mycobacteriol; 2014 Dec; 3(4):276-82. PubMed ID: 26786627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
    Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
    Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
    Vilchèze C; Jacobs WR
    Microbiol Spectr; 2014 Aug; 2(4):MGM2-0014-2013. PubMed ID: 26104204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in
    Abbadi BL; Rodrigues-Junior VDS; Dadda ADS; Pissinate K; Villela AD; Campos MM; Lopes LGF; Bizarro CV; Machado P; Sousa EHS; Basso LA
    Front Microbiol; 2018; 9():880. PubMed ID: 29765372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
    ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potential inhibitors of
    Kamera S; Sharma VK; Prasad V B; Garlapati A
    J Biomol Struct Dyn; 2024 Sep; 42(15):7957-7971. PubMed ID: 37526169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
    Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
    Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
    Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis.
    Vilchèze C; Morbidoni HR; Weisbrod TR; Iwamoto H; Kuo M; Sacchettini JC; Jacobs WR
    J Bacteriol; 2000 Jul; 182(14):4059-67. PubMed ID: 10869086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.